Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Risperidone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A known ✓ | P28223 | 14/20 | 0.92 |
| ▸ | DRD2 known ✓ | P14416 | 13/20 | 0.92 |
| ▸ | HTR2C known ✓ | P28335 | 3/20 | 0.92 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.92 |
| ▸ | DRD3 | P35462 | 4/20 | 0.92 |
| ▸ | HTR7 | P34969 | 4/20 | 0.92 |
| ▸ | HTR1A | P08908 | 4/20 | 0.92 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.92 |
| ▸ | HRH1 | P35367 | 3/20 | 0.92 |
| ▸ | ACHE | P22303 | 3/20 | 0.92 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.92 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.92 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.92 |
| ▸ | DRD1 | P21728 | 2/20 | 0.92 |
| ▸ | DRD4 | P21917 | 2/20 | 0.92 |
| ▸ | DRD5 | P21918 | 2/20 | 0.92 |
| ▸ | HTR1D | P28221 | 2/20 | 0.92 |
| ▸ | HTR1B | P28222 | 2/20 | 0.92 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.92 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.92 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Risperidone SCHEMBL5779206 | 0.99 | DRD2 (0.91) | HTR2ADRD2KCNH2DRD3HTR7 | |
| Risperidone SCHEMBL29051431 | 0.97 | DRD2 (0.92) | HTR2ADRD2KCNH2DRD3HTR7 | |
| Risperidone SCHEMBL27911 | 0.96 | DRD2 (1.00) | HTR2ADRD2KCNH2DRD3HTR7 | |
| Risperidone SCHEMBL16965766 | 0.96 | DRD2 (1.00) | HTR2ADRD2KCNH2DRD3HTR7 | |
| Risperidone SCHEMBL5070793 | 0.96 | DRD2 (1.00) | HTR2ADRD2KCNH2DRD3HTR7 | |
| Risperidone SCHEMBL29392548 | 0.96 | DRD2 (1.00) | HTR2ADRD2KCNH2DRD3HTR7 | |
| Risperidone SCHEMBL5774262 | 0.95 | DRD2 (0.98) | HTR2ADRD2KCNH2DRD3HTR7 | |
| Risperidone SCHEMBL5777424 | 0.95 | DRD2 (0.98) | HTR2ADRD2KCNH2DRD3HTR7 | |
| Risperidone SCHEMBL20578557 | 0.95 | DRD2 (0.98) | HTR2ADRD2KCNH2DRD3HTR7 | |
| Risperidone SCHEMBL28382198 | 0.95 | DRD2 (0.98) | HTR2ADRD2KCNH2DRD3HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1615923-A1 | RISPERIDONE MONOHYDROCHLORIDE | Synthon B.V. (NL) | 2006-01-18 | — | — | EP | claimed |
| US-20040266790-A1 | Risperidone monohydrochloride | SYNTHON IP INC. | 2004-12-30 | — | — | US | claimed |
| WO-2004094415-A1 | RISPERIDONE MONOHYDROCHLORIDE | SYNTHON B.V. (NL) | 2004-11-04 | — | — | WO | claimed |
| CN-110845615-B | Anti-EGFR antibodies and antibody drug conjugates | 艾伯维公司 | 2023-10-20 | — | — | CN | disclosed |
| CN-110841074-B | anti-EGFR antibodies and antibody drug conjugates | 艾伯维公司 | 2023-07-18 | — | — | CN | disclosed |
| US-7744918-B2 | Drug-containing patch | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 2010-06-29 | — | — | US | disclosed |
| EP-1661560-B1 | Transdermal patch comprising a melting point lowering agent | HISAMITSU PHARMACEUTICAL CO (JP) | 2008-11-05 | — | — | EP | disclosed |
| EP-1661560-A1 | Transdermal patch comprising a melting point lowering agent | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 2006-05-31 | — | — | EP | disclosed |
| US-20060110434-A1 | Drug-containing patch | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 2006-05-25 | — | — | US | disclosed |
| EP-1615923-A1 | RISPERIDONE MONOHYDROCHLORIDE | Synthon B.V. (NL) | 2006-01-18 | — | — | EP | disclosed |
| EP-1615924-A1 | WATER SOLUBLE SALTS OF RISPERIDONE | Synthon B.V. (NL) | 2006-01-18 | — | — | EP | disclosed |
| US-20040266791-A1 | Water soluble salts of risperidone | SYNTHON IP INC. | 2004-12-30 | — | — | US | disclosed |
| US-20040266790-A1 | Risperidone monohydrochloride | SYNTHON IP INC. | 2004-12-30 | — | — | US | disclosed |
| WO-2004094414-A1 | WATER SOLUBLE SALTS OF RISPERIDONE | SYNTHON B.V. (NL) | 2004-11-04 | — | — | WO | disclosed |
| WO-2004094415-A1 | RISPERIDONE MONOHYDROCHLORIDE | SYNTHON B.V. (NL) | 2004-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266791-A1 | Water soluble salts of risperidone | SLC6A3, ABCG2, SLC6A4 | HTR2A 155/4885DRD2 15/4885HTR2C 188/4885 |
| US-20040266790-A1 | Risperidone monohydrochloride | HTT, HTR3A, HTR3B | HTR2A 5/4885DRD2 29/4885HTR2C 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.